MRTX Forex-Nachrichten
Mirati, Aadi To Evaluate Adagrasib, Nab-sirolimus Combination To Treat NSCLC, Other Solid Tumors
Oncology company Mirati Therapeutics, Inc. (MRTX) and biopharmaceutical company Aadi Bioscience, Inc. (AADI) announced Wednesday a clinical collaboration to evaluate the combination of adagrasib, a KRASG12C selective inhibitor, and nab-sirolimus, a small molecule mTOR inhibitor complexed with human albumin in KRAS G12C mutant non-small cell lung cancer (NSCLC) and other solid tumors.
RTTNews
|
vor 829 Tagen
